# EDGAR Filing Document

**Accession Number:** 0000888721
**File Stem:** 0001193125-25-319692
**Filing Date:** 2025-12
**Character Count:** 14574
**Document Hash:** 7cd903ed92bc5716e1d42f32e76593fb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-319692.hdr.sgml**: 20251215

**ACCESSION NUMBER**: 0001193125-25-319692

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20251215

**DATE AS OF CHANGE**: 20251215

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TRINITY BIOTECH PLC
- **CENTRAL INDEX KEY:** 0000888721
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L2
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-44122
- **FILM NUMBER:** 251573163

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** IDA BUSINESS PARK
- **STREET 2:** BRAY
- **CITY:** WICKLOW
- **PROVINCE COUNTRY:** L2
- **BUSINESS PHONE:** 01135312955111

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** IDA BUSINESS PARK
- **STREET 2:** BRAY
- **CITY:** WICKLOW
- **PROVINCE COUNTRY:** L2
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DAYLI Partners, Inc.
- **CENTRAL INDEX KEY:** 0002101262

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** M5
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 15F, 201, TEHERAN-RO
- **STREET 2:** GANGNAM-GU
- **CITY:** SEOUL
- **PROVINCE COUNTRY:** M5
- **ZIP:** 00000
- **BUSINESS PHONE:** 82-2-563-0890

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 15F, 201, TEHERAN-RO
- **STREET 2:** GANGNAM-GU
- **CITY:** SEOUL
- **PROVINCE COUNTRY:** M5
- **ZIP:** 00000

### Attached PDF Documents

**Attachment 1:** `ck0000000000-ex99_21.pdf`

_No text found in this document._

**Attachment 2:** `ck0000000000-ex99_c.pdf`

_No text found in this document._

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 7)**

**Trinity Biotech plc**

*(Name of Issuer)*

**Class 'A' Ordinary Shares**

*(Title of Class of Securities)*

**896438504**

*(CUSIP Number)*

**Seung Hyun Shin**<br>c/o DAYLI Partners, Inc.<br>15F, 201, Teheran-ro, Gangnam-gu<br>Seoul M5 0000<br>82-2-563-0890

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/02/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **896438504** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**DAYLI Partners, Inc.** | Name of reporting person<br>**DAYLI Partners, Inc.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**M5** | Citizenship or place of organization<br>**M5** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.0%** | Percent of class represented by amount in Row (11)<br>**0.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **896438504** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**DAYLI TRINITY HOLDINGS, Ltd.** | Name of reporting person<br>**DAYLI TRINITY HOLDINGS, Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**M5** | Citizenship or place of organization<br>**M5** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.0%** | Percent of class represented by amount in Row (11)<br>**0.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **896438504** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**DAYLI Fountainhead Project No.3 Private Equity Fund** | Name of reporting person<br>**DAYLI Fountainhead Project No.3 Private Equity Fund** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**M5** | Citizenship or place of organization<br>**M5** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.0%** | Percent of class represented by amount in Row (11)<br>**0.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Class 'A' Ordinary Shares

**(b) Name of Issuer:**
Trinity Biotech plc

**(c) Address of Issuer's Principal Executive Offices:**
IDA Business Park, Bray, County Wicklow, L2, A98 H5C8

The purpose of this Amendment No. 7 ("Amendment No. 7") to the joint statement on Schedule 13D with respect to the Class 'A' Ordinary Shares, par value U.S. $0.0001 per share (the "Ordinary Shares"), of Trinity Biotech, plc, a company organized under the laws of Ireland (the "Issuer"), filed by MiCo Co., Ltd. ("MiCo Parent") and MiCo IVD Holdings, LLC, a Delaware limited liability company ("MiCo IVD") on December 7, 2022 (such joint statement, as amended by Amendment No. 2 to the Schedule 13D filed by MiCo IVD, Mainstream Holdings, Ltd. ("Mainstream Holdings"), Mainstream New Growth No. 1 Private Equity Fund ("Mainstream NG"), New Main Equity Co., Ltd. ("New Main Equity") and Kim Chang-hee (together with Mainstream Holdings, Mainstream NG and New Main Equity, the "New Main Equity Filers") on January 2, 2024, Amendment No. 3 to the Schedule 13D filed by MiCo IVD, DAYLI TRINITY HOLDINGS, Ltd., a limited company incorporated in South Korea ("DAYLI Holdings"), DAYLI Fountainhead Project No. 3 Private Equity Fund, a private equity fund incorporated in South Korea ("DAYLI Fountainhead"), and DAYLI Partners, Inc., a corporation incorporated in South Korea (together with DAYLI Holdings and DAYLI Fountainhead, the "DAYLI Filers") on December 19, 2024 ("Amendment No. 3"), Amendment No. 5 to the Schedule 13D filed by MiCo IVD, AI n M net Ltd. ("AI n M") and Wonyong Park on December 4, 2025, and Amendment No. 6 to the Schedule 13D filed by MiCo IVD, AI n M and Joon Ho Lee on December 10, 2025, the "Original Schedule 13D"), to which the DAYLI Filers previously joined as reporting persons as reported in Amendment No. 3 to the Schedule 13D filed on December 19, 2024, filed jointly by the DAYLI Filers, is to report the change in the beneficial ownership of the DAYLI Filers as a result of the execution and consummation of the 2025 MiCo IVD Purchase (as defined below) by AI n M on December 2, 2025 and the revocation of the Joint Filing Agreement by the DAYLI Filers initially filed as an exhibit to the Original Schedule 13D on December 19, 2024. Capitalized terms used but not defined herein have the respective meanings given to them in the Original Schedule 13D and, except as otherwise provided below, the Original Schedule 13D is incorporated herein by reference.

On January 2, 2024, MiCo Parent filed an Amendment No. 1 to the Original Schedule 13D ("Amendment No. 1") to report its sale of all of its equity interests in MiCo IVD to Mainstream Holdings and, on December 20, 2024, the New Main Equity Filers filed a Schedule 13D intended to serve as Amendment No. 4 to the Schedule 13D ("Amendment No. 4") to report the sale by Mainstream Holdings of all of its equity intetersts in MiCo IVD to DAYLI Holdings. Amendment No. 1 and Amendment No. 4 speak only of the beneficial ownership interests of MiCo Parent and the New Main Equity Filers, respectively, and the disclosures provided therein shall be disregarded in their entirety for the purposes of this Amendment No. 7, except that the exhibits included in response to Item 7 of each of Amendment No. 1 and Amendment No. 4 shall be incorporated herein by reference as described in Item 7 below.

This Amendment No. 7 is being filed by the DAYLI Filers only and the disclosures provided herein shall have no effect on disclosures previously provided by any other reporting person.

**Item 4. Purpose of Transaction**

Item 4 of the Original Schedule 13D is hereby amended by inserting the following new paragraph to the end:

On December 2, 2025, DAYLI Holdings and AI n M completed the 2025 MiCo IVD Purchase, following which time the DAYLI Filers have no equity interest in MiCo IVD and do not, directly or indirectly, have any equity interest in the Issuer.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5(a) of the Original Schedule 13D is hereby amended and restated in full as follows:

The information set forth under the final paragraph of Item 4 and the cover page of this Amendment No. 7 is incorporated herein by reference into this Item 5.

Following the completion of the 2025 MiCo IVD Purchase by AI n M, the DAYLI Filers are no longer deemed to beneficially own any Ordinary Shares.

**(b)**
Item 5(b) of the Original Schedule 13D is hereby amended and restated in full as follows:

The information set forth under the final paragraph of Item 4 and the cover page of this Amendment No. 7 is incorporated herein by reference into this Item 5.

Following the completion of the 2025 MiCo IVD Purchase by AI n M, the DAYLI Filers are no longer deemed to beneficially own any Ordinary Shares.

**(c)**
Item 5(c) of the Original Schedule 13D is hereby amended and restated in full as follows:
Except as set forth in the Original Schedule 13D and this Amendment No. 7, neither the DAYLI Filers nor, to the best knowledge of the DAYLI Filers, any other person named in Item 2, has engaged in any transaction in Ordinary Shares during the past 60 days.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** DAYLI Partners, Inc.

**Signature:** /s/ Shin Seung Hyun

**Name/Title:** Shin Seung Hyun/CEO

**Date:** 12/15/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** DAYLI TRINITY HOLDINGS, Ltd.

**Signature:** /s/ Wonyong Park

**Name/Title:** Wonyong Park/CEO

**Date:** 12/15/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** DAYLI Fountainhead Project No.3 Private Equity Fund

**Signature:** /s/ Wonyong Park

**Name/Title:** Wonyong Park/Senior Manager

**Date:** 12/15/2025